13D Filing: RA Capital Management and Dicerna Pharmaceuticals Inc (DRNA)

Page 3 of 7 – SEC Filing

 

 

1

Names of Reporting Persons.

Peter Kolchinsky

2 Check the Appropriate Box if a Member of a Group (See Instructions)
(a) [ ]
(b) [ ]
3 SEC Use Only
4

Source of Funds (See Instructions):

AF

5

Check if disclosure of legal proceedings
is required pursuant to Items 2(d) or 2(e):

[ ]

6 Citizenship or Place of Organization.    United States

Number

of Shares

Beneficially

Owned by

Each

Reporting

Person With

7 Sole Voting Power     0
8 Shared Voting Power      4,588,536
9 Sole Dispositive Power     0
10 Shared Dispositive Power  4,588,536
11

Aggregate Amount Beneficially Owned by
Each Reporting Person

4,588,536

12 Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)     [ ]
13

Percent of Class Represented by Amount
in Row (11)

19.9%2

14

Type of Reporting Person (See Instructions)

HC, IN

 _________________

2 Represents 2,428,571 shares
of the Common Stock of the Issuer and 2,159,965 shares of the Common Stock issuable upon conversion of Preferred Stock which constitute
approximately 19.94% of the class outstanding. The percentage calculation assumes that there are currently 20,848,503 outstanding
shares of the Common Stock of the Issuer, based on the Issuer’s Form 10-Q for the quarterly period ended September 30, 2017
as filed with the SEC on November 2, 2017.

 

Follow Dicerna Pharmaceuticals Inc (NASDAQ:DRNA)